PAracetamol Treatment in Hypertension: effect on Blood Pressure (PATH-BP) study

Webb, David (Principal Investigator)

Status	Finished
Effective start/end date	1/11/14 → 31/07/19

Funding

UK-based charities: £149,174.00

2 Article

Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP Biomarker sub-study)
Scullion, K., MacIntyre, I. M., Sloan-Dennison, S., Clark, B., Fineran, P., Mair, J., Creasey, D., Rathmell, C., Faulds, K., Graham, D., Webb, D. J. & Dear, J. W., 10 Apr 2024, In: Toxicological Sciences. 199, 2, p. 203–209
Research output: Contribution to journal › Article › peer-review

Open Access
File
Regular acetaminophen use and blood pressure in people with hypertension The PATH-BP Trial
MacIntyre, I., Turtle, E. J., Farrah, T. E., Graham, C., Dear, J. W., Webb, D. J., for the PATH-BP (Paracetamol in Hypertension–Blood Pressure) Investigators, Melville, V. & Caparrotta, T. M., 7 Feb 2022, In: Circulation.
Research output: Contribution to journal › Article › peer-review

Open Access
File